Last reviewed · How we verify
Misoprostol-only medication abortion regimen
Misoprostol is a prostaglandin analog that causes uterine contractions and cervical dilation to induce abortion.
Misoprostol is a prostaglandin analog that causes uterine contractions and cervical dilation to induce abortion. Used for Medical abortion (pregnancy termination up to specified gestational age).
At a glance
| Generic name | Misoprostol-only medication abortion regimen |
|---|---|
| Sponsor | Ibis Reproductive Health |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Misoprostol binds to prostaglandin receptors on uterine smooth muscle, triggering strong contractions that expel the pregnancy. It also softens and dilates the cervix, facilitating passage of pregnancy tissue. When used alone (without mifepristone), higher doses and longer treatment duration are required compared to combination regimens.
Approved indications
- Medical abortion (pregnancy termination up to 12 weeks gestation)
Common side effects
- Abdominal cramping
- Vaginal bleeding
- Nausea
- Diarrhea
- Vomiting
- Fever
- Chills
Key clinical trials
- The Misoprostol-Only Regimen Evidence Study (PHASE4)
- Evaluation of Telemedicine Medical Abortion Service in Ecuador
- Comparison of Two Different Drug Regimens for Medical Treatment of Early Pregnancy Loss (PHASE4)
- Study of Clinic-based vs. Self-use of a Misoprostol-only Regimen for Induced Abortion
- Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: